MetaVia Inc. (MTVA) Cash Flow Statement

NASDAQ: MTVAOperating cash, capex, free cash flow and buybacks.

Where MTVA’s cash came from and went, 2025

December 31, 2025 · U.S. dollars
Cash from operations
−$15.7M
Capital expenditures
$2,000
Free cash flow
−$15.7M
Returned to shareholders
—
Change in cash
−$5.7M
cash at year-end $10.3M
Shares issued: $11.2MShares issued$11.2MDrawn from cash: $5.7MDrawn from cash$5.7MCash used in operations: $15.7MCash used in operations$15.7M · 93%Other financing: $1.2MOther financing$1.2M · 7%Capital expenditures: $2,000Capital expenditures$2,000 · 0%$16.9M
Cash from operations
−$15.7M
Shares issued
+$11.2M
Other financing
−$1.2M
Change in cash
−$5.7M

Drawn to scale: where the cash came from and how it was used. Hover for values.

MTVA operating cash flow, capex and free cash flow

Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)

MTVA cash flow trends, 2016–2025

MetaVia Inc. cash flow trends
MetricTrendThenLatestChange
Operating cash flow−$11.0M2016−$15.7M2025—
Capital expenditures$02016$2,0002025—
Free cash flow−$11.0M2016−$15.7M2025—
Stock-based compensation$1.7M2016$411,0002025−14.7%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

MTVA cash flow by activity

OperatingInvestingFinancingChange in cash

MTVA net income vs operating cash flow

Net incomeOperating cash flow

Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).

MTVA cash flow statement

MetaVia Inc. annual cash flow statement
2025202420232022202120202019201820172016
Operating activities
Net income−$13.0M−$27.6M−$12.5M−$14.0M−$15.3M−$29.7M−$21.3M−$15.5M−$33.4M−$14.6M
Depreciation & amortization$19,000$20,000$6,000$20,000$48,000$46,000$17,000———
Stock-based compensation$411,000$538,000$222,000$854,000$662,000$699,000$118,000—$5.3M$1.7M
Change in working capital−$2.9M$2.6M$4.4M−$1.2M−$584,000$809,000$744,000−$778,000$1.1M$1.9M
Other non-cash items−$228,000−$293,000−$3.0M$2.5M$24,000$17.4M$13.4M$1.9M$137,000−$93,000
Cash from operating activities−$15.7M−$24.7M−$10.8M−$11.7M−$15.1M−$10.8M−$7.0M−$14.5M−$26.9M−$11.0M
Investing activities
Capital expenditures−$2,000−$8,000−$50,000$0−$3,000−$4,000−$214,000−$3,000$0$0
Investments (net)—−$8,000−$50,000$8,000−$586,000$69,000————
Acquisitions & other investing$0$8,000$50,000$0$3,000$4,000−$5.8M$0——
Cash from investing activities−$2,000−$8,000−$50,000$8,000−$586,000$69,000−$6.1M−$3,000——
Financing activities
Shares issued$11.2M$20.0M$0$32.2M$24.0M$7.5M$0$0$0$0
Other financing−$1.2M−$1.7M−$80,000−$3.6M−$2.0M−$642,000$24.2M$17.2M$21.3M$31.5M
Cash from financing activities$10.0M$18.3M−$80,000$28.7M$22.0M$6.9M$24.2M$17.2M$21.3M$31.5M
Summary
Net change in cash−$5.7M−$6.4M−$10.9M$17.0M$6.3M−$3.8M$11.1M$2.8M−$5.6M$20.4M
Cash at end of period$10.3M$16.0M$22.4M$33.4M$16.4M$10.1M$13.9M$2.8M$18.5M$24.0M
Free cash flow−$15.7M−$24.7M−$10.8M−$11.7M−$15.1M−$10.8M−$7.3M−$14.5M−$26.9M−$11.0M

Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.

MTVA cash generation

In fiscal 2025 (ended December 31, 2025), MetaVia generated -$15.7 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$15.7 million. Cash and equivalents fell by $5.7 million over the year.

Related: MTVA income statement, MTVA balance sheet. See the MTVA stock overview for the latest quote and news.

MTVA cash flow FAQ

What is MetaVia's free cash flow?

MetaVia's free cash flow was -$15.7 million in fiscal 2025: -$15.7 million of operating cash flow minus $0.0 million of capital expenditures It was -$24.7 million a year earlier..

How much cash does MetaVia generate from operations?

MetaVia generated -$15.7 million of cash from operating activities in fiscal 2025.

How much does MetaVia spend on capital expenditures?

MetaVia spent $0.0 million on capital expenditures in fiscal 2025, compared with $0.0 million the year before.

Biotechnology: cash flow